The semi-annual rebalancing of the Hang Seng Composite Index, announced by Hang Seng Indexes Company on Aug. 21, will take effect Sept. 7, triggering a corresponding adjustment to the universe of Hong Kong-listed stocks eligible for southbound investment through the Mainland–Hong Kong Stock Connect program. But this time, the market’s long-reliable playbook for profiting from that reshuffle has stopped working.
Huatai Securities estimates that 52 stocks will be added to the Connect eligible list and 15 removed when the changes go live after the close on Sept. 4. For years, buying ahead of such inclusions and riding the wave of mandatory southbound fund flows was a textbook arbitrage. That edge has now collapsed into negative territory.
A New Cohort, Heavily Weighted to Tech and Biotech
The incoming cohort is concentrated in sectors with high volatility and speculative appeal:
Information Technology (19 names): MANYCORE TECH, Coohom (群核科技), Feisu Innovation (飞速创新), Zhongke Wenge (中科闻歌), Haiqing Zhiyuan (海清智元), Yunyinggu Technology (云英谷科技), Kaileshi Technology (凯乐士科技), Ledong Robotics (乐动机器人), Huaxida (华曦达), SENASIC (琻捷, 06675.HK), Hantian Tiancheng (瀚天天成), Aixin Yuanzhi (爱芯元智, 0600.HK), Fourier (傅里叶), Yunji (云迹, 2670.HK), Xianguan Intelligent (仙工智能), Ketuo Co., Ltd. (科拓股份), Chuangxiang 3D (创想三维), Extreme Vision (极视角), and UISEE (驭势科技). The batch includes end-side sensing and computing chip names such as SENASIC, image sensor maker Changguang Chenxin (长光辰芯, 03277.HK), optical computing pioneer Lightspeed (曦智科技, 01879.HK), and display driver chip vendor Yunyinggu.
Healthcare (15 names): Deshi-B (德适-B), Jitai Technology-P (剂泰科技-P), Henlius (复宏汉霖, 2696.HK), Zhen Health Medical-B (真健康医疗-B), Ascletis Pharma-B (歌礼制药-B, 1672.HK), Danuo Pharmaceutical-B (丹诺医药-B), Harbour BioMed-B (和铂医药-B, 2142.HK), Maike Medical-B (麦科医药-B), RiboBio-B (瑞博生物-B), Yingpai Pharmaceutical-B (英派药业-B), Tianchen Biotechnology-B (天辰生物-B), Tianxing Medical (天星医疗), CStone Pharmaceuticals-B (基石药业-B, 2616.HK), Libang Pharmaceutical-B (礼邦医药-B), and Jinhai Medical Technology (今海医疗科技).
Industrials (8): Sige New Energy (思格新能), Changguang Chenxin (长光辰芯), Haiguang Xinzheng (海光芯正), Tsugami Machine Tool China (津上机床中国, 1651.HK), Tuopu CNC (拓璞数控), Impro Precision (鹰普精密, 1286.HK), Harbin Electric Corporation (哈尔滨电气, 1133.HK), and Huayan Robotics (华沿机器人, 1021.HK).
Raw Materials (3): Tongguan Gold (潼关黄金, 0340.HK), China XLX Fertiliser (中国心连心化肥, 1866.HK), and Shougang Langze (首钢朗泽).
Financials (2): Yunfeng Financial Group (云锋金融, 0376.HK) and Baige Online (白鸽在线, 2672.HK).
Consumer Discretionary (3) & Staples (2): Shenyan Intelligent (深演智能), Yingxing Holdings (应星控股), and Zejing Co., Ltd. (泽景股份); plus Xunlong Technology (鲟龙科技) and Liuliumei (溜溜梅).
The Historical Pattern — And Its Collapse
Since February 2017, newly included Connect names have delivered consistent positive excess returns against the Hang Seng Index during the window from the adjustment announcement to the effective date. That relationship has now broken. During the July 1 – Aug. 22 window, the current cohort of prospective inclusions underperformed the Hang Seng Composite by an average of -16.0% and a median of -19.1% — a dramatic reversal from the historical norm.
The drag is especially severe for the 14 names that went public in June. From end-June onward, these recent IPOs have posted average relative declines of 25.9% versus the Hang Seng Composite.
💡 The inflection is unambiguous: what was once a reliable “buy-the-rumor” trade has become a “sell-the-news” event.
Why the Edge Has Vanished
Huatai attributes the inversion to three converging forces:
Southbound inflows have decelerated on a marginal basis, starving the inclusion trade of its primary fuel.
Pre-positioning has become overcrowded. With the strategy widely known, capital front-runs the announcement, leaving little alpha for the announcement-to-effective-date window itself.
Quality dispersion within the cohort has widened. The heavy weighting toward early-stage biotech and recently listed tech names means the batch’s aggregate fundamentals are weaker and more heterogeneous than in prior cycles.
What It Means for Deletions
Investors should not overlook the other side of the ledger. The 15 names slated for removal will lose access to southbound liquidity. According to LiveReport data, the deleted names include Nissin Foods (日清食品), JS Global Lifestyle (JS环球生活), Yidu Tech (医渡科技), and Haichang Ocean Park (海昌海洋公园), among others.
The Bottom Line
The September 2026 Connect reshuffle marks a regime shift. While the incoming slate offers genuine optionality in high-beta sectors — particularly IT and healthcare — the structural tailwind that made “Connect inclusion” a near-automatic trade has dissipated. With southbound flows moderating and the market having thoroughly gamed the timing, the burden of proof now rests on fundamentals, not mere eligibility.